Immunogenicity and Safety of the Adjuvanted Respiratory Syncytial Virus Prefusion F Protein-Based Vaccine When Co-administered With the Adjuvanted Recombinant Herpes Zoster Subunit Vaccine in Adults ≥ 50 Years of Age
Clinical Infectious Diseases · 2026
DOI: 10.1093/cid/ciag208 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Clinical Infectious Diseases, 2026. Verfasst von Jean-François Roussy und 14 weiteren Autor:innen. Beteiligte Einrichtung: DIEX Research, Québec, Québec, Canada. Hauptthemen laut MEDLINE: Herpes Zoster Vaccine, Respiratory Syncytial Virus Vaccines, Respiratory Syncytial Virus Infections, Adjuvants, Immunologic. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: GSK.
Abstract (Originalsprache)
Background
Co-administration of AS01E-adjuvanted respiratory syncytial virus vaccine (adjuvanted RSVPreF3) and AS01B-adjuvanted recombinant herpes zoster subunit vaccine (RZV), although not contraindicated, has not been previously studied in clinical trials.
Methods
This phase III, open-label, randomized (1:1) trial evaluated the immunogenicity, safety, and reactogenicity of adjuvanted RSVPreF3 when co-administered with RZV in ≥50-year-olds. The 2 vaccines were either co-administered at visit 1 (day [D] 1; Co-Ad), or were given sequentially, 1 month apart (RZV dose 1 at D1, adjuvanted RSVPreF3 at D31; Control). All participants received RZV dose-2 at D61. Non-inferiority of humoral immune responses was demonstrated if 95% confidence interval (CI) upper limits for geometric mean RSV-A/B neutralizing titers (GMT) and varicella-zoster virus anti-glycoprotein E (anti-gE) antibody concentration (GMC) ratios (Control/Co-Ad) were ≤1.5. Safety and reactogenicity were secondary endpoints.
Results
Overall, 530 participants (Co-Ad = 265; Control = 265) were vaccinated. Neutralizing GMT ratios for RSV-A (1.1 [95% CI = 1.0–1.4]) and RSV-B (1.0 [0.8–1.2]), and anti-gE antibody GMC ratio (1.2 [1.1–1.4]) met non-inferiority criteria. Within 7 days post-vaccination, 71.7% (Co-Ad: post-RZV dose 1 and adjuvanted RSVPreF3; grade [Gr] 3 = 3.9%), 58.5% (Control: post-RZV dose 1; Gr3 = 1.9%), and 47.8% (Control: post-adjuvanted RSVPreF3; Gr3 = 1.2%) of participants reported solicited administration-site adverse events (AEs). Post-visit 1, 73.6% (Gr3 = 9.3%) of Co-Ad and 60.4% (Gr3 = 6.2%) of control participants reported solicited systemic AEs. Within 30 days post-any vaccination, 23.4% (Gr3 = 0.8%) of Co-Ad and 30.2% (Gr3 = 1.1%) of control participants reported unsolicited AEs. No fatal or related serious AEs were reported.
Conclusions
Immunogenicity, reactogenicity, and safety data support the co-administration of adjuvanted RSVPreF3 and RZV. Clinical Trials Registration NCT05966090.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- DIEX Research, Québec, Québec, Canada.
- DELRIGHT Research, New Orleans, Louisiana, USA.
- Albion Finch Medical Center, Toronto, Ontario, Canada.
- Dawson Clinical Research, Guelph, Ontario, Canada.
- LMC Healthcare/Centricity Research, Toronto, Ontario, Canada.
- Aggarwal and Associates, Brampton, Ontario, Canada.
ORCID-Profile: Alexander Abitbol, Brian A Smith, Marie Van der Wielen
Förderung
- GSK
Zitieren
APA
Roussy, J. F., Dennis, P., Gupta, A. K., Wallace, G., Abitbol, A., Aggarwal, N., Surber, J. G., Lee, T., Smith, B. A., Gérard, C., Hailemariam, H. A., David, M. P., Jastorff, A. M., Van der Wielen, M., & RSV-020 Study Group (2026). Immunogenicity and Safety of the Adjuvanted Respiratory Syncytial Virus Prefusion F Protein-Based Vaccine When Co-administered With the Adjuvanted Recombinant Herpes Zoster Subunit Vaccine in Adults ≥ 50 Years of Age. Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciag208
Vancouver
Roussy JF, Dennis P, Gupta AK, Wallace G, Abitbol A, Aggarwal N, et al. Immunogenicity and Safety of the Adjuvanted Respiratory Syncytial Virus Prefusion F Protein-Based Vaccine When Co-administered With the Adjuvanted Recombinant Herpes Zoster Subunit Vaccine in Adults ≥ 50 Years of Age. Clinical Infectious Diseases. 2026. doi:10.1093/cid/ciag208
BibTeX
@article{Roussy2026,
author = {Roussy, Jean-François and Dennis, Patrick and Gupta, Anil K and Wallace, Garry and Abitbol, Alexander and Aggarwal, Naresh and Surber, Joseph G and Lee, Theodore and Smith, Brian A and Gérard, Catherine and Hailemariam, Hiwot Amare and David, Marie-Pierre and Jastorff, Archana M and Van der Wielen, Marie and RSV-020 Study Group, RSV-020 Study Group},
title = {Immunogenicity and Safety of the Adjuvanted Respiratory Syncytial Virus Prefusion F Protein-Based Vaccine When Co-administered With the Adjuvanted Recombinant Herpes Zoster Subunit Vaccine in Adults ≥ 50 Years of Age},
journal = {Clinical Infectious Diseases},
year = {2026},
doi = {10.1093/cid/ciag208}
}
EUVIMED